| 引用本文: | 梅峥嵘,谭湘萍,黄汉辉,曾晓敏.葛根素对阿尔茨海默病细胞模型Aβ蛋白的抑制作用[J].中国现代应用药学,2015,32(1):5-9. |
| MEI Zhengrong,TAN Xiangping,HUANG Hanhui,ZENG Xiaomin.Puerarin Against Alzheimer’s Disease by Inhibition β-amyloid Protein[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(1):5-9. |
|
| 摘要: |
| 目的 在过表达β淀粉样前体蛋白的SH-SY5Y细胞上(SH-SY5Y/APP695)观察葛根素对β淀粉样蛋白(β-amyloid protein，Aβ)生成的作用，探讨其防治阿尔茨海默病的机制。方法 葛根素2.5，5和10 μmol·L-1处理SH-SY5Y/APP细胞24 h，MTT法检测细胞活力，ELISA试剂盒测定细胞外Aβ1-40和Aβ1-42水平；Western blot蛋白质印迹法检测APP及β-分泌酶的蛋白表达变化；荧光法测β-分泌酶的活性；RT-PCR法检测β-分泌酶转录的变化。结果 葛根素可剂量依赖性的减少SH-SY5Y/APP695细胞外Aβ1-40、Aβ1-42的水平；酶活性分析显示2.5，5和10 μmol·L-1的葛根素分别抑制了15%，30%和40%β-分泌酶的活性。Western blot印迹结果显示，葛根素能剂量依赖性抑制β-分泌酶蛋白表达，2.5，5和10 μmol·L-1的葛根素使β-分泌酶的蛋白表达分别减少至82%，71%和45%，与空白对照组比较差异均具有统计学意义(P<0.05)。结论 葛根素通过下调β-分泌酶蛋白的表达、抑制β-分泌酶的活性减少Aβ的形成，这可能是葛根素防治阿尔茨海默病作用的重要机制之一。 |
| 关键词: 阿尔茨海默病 葛根素 β淀粉样蛋白 |
| DOI： |
| 分类号: |
| 基金项目:广东省中医药强省基金项目(20111257) |
|
| Puerarin Against Alzheimer’s Disease by Inhibition β-amyloid Protein |
|
MEI Zhengrong, TAN Xiangping, HUANG Hanhui, ZENG Xiaomin
|
|
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China
|
| Abstract: |
| OBJECTIVE To investigate the effects of puerarin on β-amyloid precursor protein (APP) processing on SH-SY5Y cells transfected with human APP695 cDNAs and to explore the mechanism of puerarin on Alzheimer’s disease(AD). METHODS SH-SY5Y cells transfected with human APP695 cDNAs were cultured with 2.5, 5, 10 μmol·L-1 puerarin，and cell survival was detected by MTT assay. The levels of Aβ1-40 and Aβ1-42 in conditioned were measured medium by using ELISA kit. The expressions of APP and b-secretase were detected by Western blot. The activity of secretase were measured by using a fluorescence spectrophotometer, the mRNA transcription of β-secretase were detected by RT-PCR. RESULTS Puerarin could dose-dependently reduce the levels of extracellular Aβ1-40 or Aβ1-42. After treatment with 2.5, 5 and 10 μmol·L-1 puerarin for 24 h, the activity of β-secretase was decreased 15%, 30% and 40%, respectively(P<0.05). Compared with control group, puerarin 2.5, 5 and 10 μmol·L-1 decreased β-secretase protein express to 82%, 71% and 45%, respectively(P<0.05). CONCLUSION Puerarin decreases Aβ levels by inhibit b-secretase expression and β-secretase activity, which may account for molecular mechanisms underlying the therapeutic efficacy of puerarin in AD patients. |
| Key words: Alzheimer’s disease puerarin amyloid |
